Tag: AstraZeneca

AstraZeneca announces the completion of the clinical programme to support the transition of Breztri to next-generation propellant with near-zero Global Warming Potential

Stuart Mitchell

AstraZeneca has completed the studies that support the first regulatory filings for the transition of Breztri/Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF) to an innovative, next-generation propellant with 99.9% lower Global Warming Potential than propellants used in currently available inhaled medicines. Breztri is a triple-combination therapy for chronic obstructive pulmonary disease (COPD) and will be the first medicine in AstraZeneca’s portfolio of pressurised-metered dose inhalers (pMDIs) to transition to the new propellant. Clinical programmes for the transition of AstraZeneca’s wider pMDI portfolio to the new propellant are underway. While pMDIs contribute…

Read More

AstraZeneca announces $400 million investment in reforestation and biodiversity in support of climate action and human health

Stuart Mitchell

AstraZeneca has announced a $400 million investment in its global AZ Forest programme, raising its commitment to plant 200 million trees by 2030 and ensure their long-term survival. This includes new or expanded projects in Brazil, India, Vietnam, Ghana and Rwanda that will contribute to the Company’s climate action, restore nature, promote biodiversity and build ecological and community resilience, spanning over 100,000 hectares worldwide. The investment builds on AstraZeneca’s initial AZ Forest commitment, announced in 2020, to plant and maintain more than 50 million trees by the end of 2025…

Read More

AstraZeneca progresses Ambition Zero Carbon programme with Honeywell partnership to develop next-generation respiratory inhalers

Stuart Mitchell

AstraZeneca and Honeywell will partner to develop next-generation respiratory inhalers using the propellant HFO-1234ze, which has up to 99.9% less Global Warming Potential (GWP) than propellants currently used in respiratory medicines. This announcement coincides with the publication of the Company’s annual Sustainability Report and demonstrates progress on its flagship sustainability programme, Ambition Zero Carbon. The Report also shows that the entirety of AstraZeneca’s imported electricity now comes from renewable sources and that the Company has achieved a 59% reduction in its Scope 1 and 2 greenhouse gas (GHG) emissions since…

Read More

AstraZeneca’s ‘Ambition Zero Carbon’ strategy to eliminate emissions by 2025 and be carbon negative across the entire value chain by 2030

Stuart Mitchell

AstraZeneca has unveiled an ambitious programme for zero carbon emissions from its global operations by 2025 and to ensure its entire value chain is carbon negative by 2030, bringing forward decarbonisation plans by more than a decade. Launched today at the World Economic Forum (WEF) Annual Meeting in Davos, Switzerland, AstraZeneca’s ‘Ambition Zero Carbon’ strategy accelerates the Company’s existing science-based targets, doubling energy productivity and using renewable energy for both power and heat, as well as switching to a 100% electric vehicle fleet five years ahead of schedule. The Company…

Read More

AstraZeneca electrifies its global vehicle fleet

Stuart Mitchell

The Climate Group has announced that global pharmaceutical giant AstraZeneca will join its business leadership initiative on electric vehicles, EV100. AstraZeneca is setting new standards for industry leadership on tackling air pollution and climate change by announcing a switch of its 16,000 strong vehicle fleet to electric to limit the health impacts of air pollution across the globe. The company, which is headquartered in Cambridge, UK, with major corporate sites in the US and Sweden, is the first pharmaceutical company to join the EV100 initiative by The Climate Group, the…

Read More